Curettage of Atypical cartilage tumor tied to overall increased fracture risk among males with larger lesions
Atypical cartilage tumor (ACT), which are benign growths, are commonly found in the medullary cavity of long bones. They are often discovered during the diagnostic process for musculoskeletal issues. It was previously classified as grade 1 chondrosarcoma, but in 2013, WHO changed the nomenclature due to its benign clinical behaviour and good prognosis, with a 5-year survival rate of...
Atypical cartilage tumor (ACT), which are benign growths, are commonly found in the medullary cavity of long bones. They are often discovered during the diagnostic process for musculoskeletal issues. It was previously classified as grade 1 chondrosarcoma, but in 2013, WHO changed the nomenclature due to its benign clinical behaviour and good prognosis, with a 5-year survival rate of 83-99%.
A recent study published in the Journal of Orthopaedic Surgery and Research has concluded that the curettage of ACT results in an overall fracture risk of 6%. This risk is particularly increased for males with larger lesions.
The debate on the curettage of ACT is ongoing. Curettage causes bone defects that lead to fractures. This study aimed to determine the postoperative fracture risk after curettage of chondroid tumours and patient-specific factors affecting fracture risk.
Two hundred ninety-seven adult patients who underwent curettage with ACT followed by phenolisation and augmentation were evaluated retrospectively. Variables included sex, age, tumour size, location, augmentation type, and plate fixation. Radiologically, the presence of a fracture was diagnosed. The patients had at least 90 days of follow-up.
Key findings from the study are:
· The study had 183 females and 114 males, with a median follow-up of 3.2 years.
· The mean diameter of the lesions was 4.5 cm.
· 259 Patients received augmentation with allograft bone, 11 with Polymethyl methacrylate (PMMA) and 27 did not receive augmentation.
· Overall fracture risk was 6%.
· For postoperative fractures, the male sex and lesion size larger than 3.8 cm were risk factors.
They said our study demonstrates that augmentation using allograft bone chips or PMMA after intralesional curettage of an ACT does not influence fracture risk.
A low number of fractures prohibited stratified or multivariable analysis to account for potential confounding; the window size, insufficient power and predefined follow-up of 90 days were some of the study's limitations.
Our study included a large group (297 patients) with a prolonged follow-up period. This study can function as a base for further research toward active surveillance, given the high postoperative fracture risk, especially for men with large tumor lesions.
This research serves as a foundation for future investigations into active surveillance, given the elevated risk of postoperative fractures, particularly in men with large tumor burdens, they said.
Reference:
Krebbekx, G.G.J., Fris, F.J., Schaap, G.R. et al. Fracture risk after intralesional curettage of atypical cartilaginous tumors. J Orthop Surg Res 18, 851 (2023). https://doi.org/10.1186/s13018-023-04215-4
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd